M&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPT

Key Points

• M&T Bank Corp purchased a new Q4 position of 83,348 shares of Sarepta Therapeutics, valued at about $1.79 million and representing roughly 0.08% ownership.
• Analysts are mixed—nine Buy, thirteen Hold and six Sell ratings—giving a consensus rating of "Hold" and an average price target of $32.63.
• Sarepta reported a large quarterly EPS miss (‑$3.58 vs. ‑$0.87 expected) with revenue of $442.9M (down 32.7% YoY); the company has a market cap around $2.22B and the stock trades near $21.

M&T Bank Corp purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 83,348 shares of the biotechnology company's stock, valued at approximately $1,794,000. M&T Bank Corp owned 0.08% of Sarepta Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Yousif Capital Management LLC boosted its holdings in Sarepta Therapeutics by 1.9% in the 4th quarter. Yousif Capital Management LLC now owns 25,704 shares of the biotechnology company's stock valued at $541,000 after purchasing an additional 481 shares during the period. Arizona State Retirement System boosted its holdings in Sarepta Therapeutics by 2.8% in the 3rd quarter. Arizona State Retirement System now owns 26,165 shares of the biotechnology company's stock valued at $504,000 after purchasing an additional 717 shares during the period. Sound View Wealth Advisors Group LLC boosted its holdings in Sarepta Therapeutics by 6.1% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 12,695 shares of the biotechnology company's stock valued at $245,000 after purchasing an additional 728 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company's stock valued at $396,000 after purchasing an additional 744 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Sarepta Therapeutics by 1.8% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,208 shares of the biotechnology company's stock valued at $829,000 after purchasing an additional 758 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SRPT. Weiss Ratings raised shares of Sarepta Therapeutics from a "sell (d-)" rating to a "sell (d)" rating in a report on Wednesday, April 22nd. Wedbush boosted their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, March 26th. Wall Street Zen raised shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Sarepta Therapeutics from $12.00 to $14.00 and gave the company a "sell" rating in a report on Thursday, March 26th. Finally, Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a report on Thursday, March 26th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $32.63.

Sarepta Therapeutics Trading Up 0.4%

Shares of Sarepta Therapeutics stock opened at $21.06 on Wednesday. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -2.50, a PEG ratio of 0.32 and a beta of 0.29. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. Sarepta Therapeutics, Inc. has a 12-month low of $10.41 and a 12-month high of $64.80. The firm's 50-day moving average price is $19.48 and its two-hundred day moving average price is $20.33.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($2.71). The firm had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company's quarterly revenue was down 32.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.90 earnings per share. On average, analysts forecast that Sarepta Therapeutics, Inc. will post 2.89 earnings per share for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company's stock, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.60% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.